Lymphatic Targeting

(GLY101)

GI System

TRIAL PHASE
MECHANISMINDICATION(S)PRODUCT NAMEPreclinicalPhase 1Phase 2Phase 3
Lymphatic Targeting
Immunological Disorders, Oncology
Glyph
(GLY101)

GI System

Lymphatic Targeting
INDICATION(S):Immunological Disorders, Oncology
NAME:Glyph (GLY101)
STAGE:Preclinical
Lymphatic Targeting

We are focused on harnessing the biology of the lymphatic system to develop novel therapeutics, including those that selectively target certain lymph nodes. The lymphatic system is a vastly underexplored circulatory network that serves a fundamental role in maintaining physiological homeostasis and immune control.

Our Lymphatic Targeting Platform represents a major advancement in potentially enhancing transport and distribution of therapeutics via the lymphatic system and targeting of certain lymph nodes. By addressing the immune system at the sites of dysregulation and immune control, this novel approach has the potential to radically transform the treatment of serious disease.


  • Our Approach to Solving the Problem
    • By addressing the immune system at the sites of dysregulation and immune control, this novel approach has the potential to radically transform the treatment of serious disease
    • Targeting the lymphatic pathway potentially enables rational design of therapeutics to modulate the immune system, representing an innovative approach to treating a broad range of serious immunological disorders, such as cancer and autoimmune diseases
    • Harnessing the biology of the lymphatic system and the endogenous trafficking of compounds through the lymphatic network enables the development of novel drugs that bypass first-pass metabolism, improve oral bioavailability, and significantly lower the risk of liver toxicity
  • Team
    • The team comprises leading experts in immunomodulation
    • Key advisors include:

      Dr. Melody Swartz, the William B. Ogden Professor in Molecular Engineering and Professor of Immunology at the University of Chicago;  

      Dr. William Charman, the Dean, Faculty of Pharmacy and Pharmaceutical Sciences, at Monash University; Dr. Christopher Porter, Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University, Melbourne and Professor of Pharmaceutics; and

      Dr. Patrick Tso, the Mary M. Emery Chair of Pathology, Director Cincinnati Mouse Metabolic Phenotyping Center

    • The team includes Dr. Rishab Shyam, Dr. Ketki Karanam, and Daniel Bonner
  • Collaborations
    • We entered into an exclusive licensing agreement with Monash University based on the pioneering research of Dr. Christopher Porter

By virtue of its architecture and distribution throughout the body, the lymphatic system potentially represents a key conduit for communicating signals at the intersection of the immune-gut-brain axis.

Our Lymphatic Targeting Platform is designed to harness the biology of the lymphatic system and the endogenous trafficking of compounds through this network to develop novel drugs that bypass first-pass metabolism, improve oral bioavailability, and significantly lower the risk of liver toxicity. In particular, the mesenteric lymph nodes, proximal to the gut, are exposed to a host of microbiome related species and serve an integral role in immune education and control.

Targeting the lymphatic pathway potentially enables rational design of therapeutics to modulate the immune system, representing an innovative approach to treating a broad range of serious immunological disorders, such as cancer and autoimmune diseases.